Overview
India Glycols Limited (NSE: INDIAGLYCO, BSE: 500201) announced its unaudited standalone financial results for Q2 FY27 and H1 FY27, covering the period ended 30 September 2026. The results pertain only to the continuing operations after the demerger of its Spirits & Biofuel Undertaking into IGL Spirits Limited and its Biopharma Undertaking into Ennature Bio Pharma Limited, both now separately listed.
Q2 FY27 Results (Standalone)
- Revenue from Operations: Rs 358.18 crore, compared with Rs 2,410.71 crore in Q2 FY26 (the prior‑year figure includes the demerged businesses and is therefore not comparable).
- EBITDA: Rs 39.34 crore versus Rs 160.25 crore in Q2 FY26.
- Profit After Tax (PAT): Rs 11.24 crore versus Rs 53.94 crore in Q2 FY26.
- Quarterly earnings per share (EPS): Rs 1.68 versus Rs 8.71 in Q2 FY26.
H1 FY27 Results (Standalone)
- Revenue from Operations: Rs 712.82 crore, down from Rs 4,913.74 crore in H1 FY26 (pre‑demerger).
- EBITDA: Rs 79.55 crore versus Rs 309.51 crore in H1 FY26.
- PAT: Rs 23.59 crore versus Rs 106.79 crore in H1 FY26.
- Half‑year EPS: Rs 3.52 versus Rs 17.25 in H1 FY26.
Demerger Details
- The Hon’ble National Company Law Tribunal (NCLT), Allahabad Bench, approved the Scheme of Arrangement among India Glycols Limited, IGL Spirits Limited and Ennature Bio Pharma Limited on 17 July 2026.
- The Scheme became effective on 1 September 2026, with an appointed date of 1 April 2026.
- Under the Scheme, the Spirits & Biofuel Undertaking was transferred to IGL Spirits Limited and the Biopharma Undertaking to Ennature Bio Pharma Limited, each continuing as separate listed entities.
- Consequently, the Q2 FY27 and H1 FY27 financials exclude the performance of these two undertakings; the Q1 FY27 figures have been restated to reflect the demerger, and the comparative figures for FY26 include the demerged businesses and are not directly comparable.
Management Commentary
- CEO Rupark Sarswat stated that the implementation of the demerger marks an important step in the evolution of India Glycols, enabling a sharper focus on its core bio‑based specialties and performance chemicals business.
- He emphasized ongoing efforts to strengthen capabilities, enhance operational efficiencies, and expand business opportunities to create sustainable long‑term value for stakeholders.
Disclaimer
- The press release is distributed under an arrangement with PRNewswire; PTI assumes no editorial responsibility.